Medical Treatments for Endometriosis-Associated Pelvic Pain
Open accessThe DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Abstract
The main sequelae of endometriosis are represented by infertility and chronic pelvic pain. Chronic pelvic pain causes disability and distress with a very high economic impact. In the last decades, an impressive amount of pharmacological agents have been tested for the treatment of endometriosis-associated pelvic pain. However, only a few of these have been introduced into clinical practice. Following the results of the controlled studies available, to date, the first-line treatment for endometriosis associated pain is still represented by oral contraceptives used continuously. Progestins represent an acceptable alternative. In women with rectovaginal lesions or colorectal endometriosis, norethisterone acetate at low dosage should be preferred. GnRH analogues may be used as second-line treatment, but significant side effects should be taken into account. Nonsteroidal anti-inflammatory drugs are widely used, but there is inconclusive evidence for their efficacy in relieving endometriosis-associated pelvic pain. Other agents such as GnRH antagonist, aromatase inhibitors, immunomodulators, selective progesterone receptor modulators, and histone deacetylase inhibitors seem to be very promising, but there is not enough evidence to support their introduction into routine clinical practice. Some other agents, such as peroxisome proliferator activated receptors-γligands, antiangiogenic agents, and melatonin have been proven to be efficacious in animal studies, but they have not yet been tested in clinical studies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Giudice, L. C., & Kao, L. C. (2004) · The Lancet · doi:10.1016/s0140-6736(04)17403-5 · Cited by 3,166
ESHRE guideline: management of women with endometriosis
Dunselman, G. A. J., Vermeulen, N., Becker, C., Calhaz-Jorge, C., D'Hooghe, T., De Bie, B., Heikinheimo, O., Horne, A. W., Kiesel, L., Nap, A., et al. (2014) · Human Reproduction · doi:10.1093/humrep/det457 · Cited by 2,211
Simoens, S., Dunselman, G., Dirksen, C., Hummelshoj, L., Bokor, A., Brandes, I., Brodszky, V., Canis, M., Colombo, G. L., DeLeire, T., et al. (2012) · Human Reproduction · doi:10.1093/humrep/des073 · Cited by 1,070
Consensus on current management of endometriosis
Johnson, N. P., Hummelshoj, L., for the World Endometriosis Society Montpellier Consortium, Abrao, M. S., Adamson, G. D., Allaire, C., Amelung, V., Andersson, E., Becker, C., Birna Árdal, K. B., et al. (2013) · Human Reproduction · doi:10.1093/humrep/det050 · Cited by 558
Vascular endothelial growth factor (VEGF) in endometriosis
Donnez, J., Smoes, P., Gillerot, S., Casanas-Roux, F., & Nisolle, M. (1998) · Human Reproduction · doi:10.1093/humrep/13.6.1686 · Cited by 531 · cited 1×
“Vascular endothelial growth factor (VEGF) is the most important angiogenic factor involved in the pathogenesis of endometriosis [107].”
BackgroundStrowitzki, T., Marr, J., Gerlinger, C., Faustmann, T., & Seitz, C. (2010) · Human Reproduction · doi:10.1093/humrep/dep469 · Cited by 381 · cited 3×
“Regarding the optimal dose, in a European randomized controlled trial (RCT), the authors concluded that 2mg/day represents the optimal dosage, because it is well tolerated and less encumbered by side effects, in particular abnormal uterine bleeding, and it has little influence on bone mineral density (BMD) [33].”
BackgroundPetta, C. A., Ferriani, R. A., Abrao, M. S., Hassan, D., Rosa e Silva, J. C., Podgaec, S., & Bahamondes, L. (2005) · Human Reproduction · doi:10.1093/humrep/deh869 · Cited by 363
Chwalisz, K., Perez, M. C., DeManno, D., Winkel, C., Schubert, G., & Elger, W. (2005) · Endocrine Reviews · doi:10.1210/er.2005-0001 · Cited by 310
Use of a levonorgestrel-releasing intrauterine device in the treatment of rectovaginal endometriosis
Fedele, L., Bianchi, S., Zanconato, G., Portuese, A., & Raffaelli, R. (2001) · Fertility and Sterility · doi:10.1016/s0015-0282(00)01759-3 · Cited by 290 · cited 1×
“Its use in the treatment of endometriosis of the rectovaginal septum provides a significant reduction in dysmenorrhea, pelvic pain, and deep dyspareunia, as well as the size of the endometriotic implants, showing levels of efficacy comparable to GnRH analogues [18, 19].”
BackgroundHarada, T., Momoeda, M., Taketani, Y., Hoshiai, H., & Terakawa, N. (2008) · Fertility and Sterility · doi:10.1016/j.fertnstert.2007.08.051 · Cited by 289
Vascular endothelial growth factor and endometriotic angiogenesis
McLaren, J. (2000) · Human Reproduction Update · doi:10.1093/humupd/6.1.45 · Cited by 269
Progestagens and anti-progestagens for pain associated with endometriosis
Brown, J., Kives, S., & Akhtar, M. (2012) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd002122.pub2 · Cited by 250
Advances in the management of endometriosis: an update for clinicians
Crosignani, P., Olive, D., Bergqvist, A., & Luciano, A. (2006) · Human Reproduction Update · doi:10.1093/humupd/dmi049 · Cited by 237
Strowitzki, T., Faustmann, T., Gerlinger, C., & Seitz, C. (2010) · European Journal of Obstetrics & Gynecology and Reproductive Biology · doi:10.1016/j.ejogrb.2010.04.002 · Cited by 227 · cited 1×
“Dienogest was significantly more effective than placebo for reducing endometriosisassociated pelvic pain [34].”
BackgroundTreatment of endometriosis with the antiprogesterone mifepristone (RU486)
Michael Kettel, L., Murphy, A. A., Morales, A. J., Ulmann, A., Baulieu, E. E., & Yen, S. S. C. (1996) · Fertility and Sterility · doi:10.1016/s0015-0282(16)58022-4 · Cited by 216
Reduced pelvic pain in women with endometriosis: efficacy of long-term dienogest treatment
Petraglia, F., Hornung, D., Seitz, C., Faustmann, T., Gerlinger, C., Luisi, S., Lazzeri, L., & Strowitzki, T. (2012) · Archives of Gynecology and Obstetrics · doi:10.1007/s00404-011-1941-7 · Cited by 200
Vercellini, P., Pietropaolo, G., De Giorgi, O., Pasin, R., Chiodini, A., & Crosignani, P. G. (2005) · Fertility and Sterility · doi:10.1016/j.fertnstert.2005.03.083 · Cited by 197 · cited 2×
“In the remaining patients, dysmenorrhea, deep dyspareunia, nonmenstrual pelvic pain, and dyschezia scores were substantially reduced without major differences between the two treatment groups [27].”
BackgroundEndometriosis: Current Therapies and New Pharmacological Developments
Vercellini, P., Somigliana, E., Viganò, P., Abbiati, A., Barbara, G., & Crosignani, P. G. (2009) · Drugs · doi:10.2165/00003495-200969060-00002 · Cited by 182
Vercellini, P., De Giorgi, O., Mosconi, P., Stellato, G., Vicentini, S., & Crosignani, P. G. (2002) · Fertility and Sterility · doi:10.1016/s0015-0282(01)02951-x · Cited by 180 · cited 1×
“Furthermore, the continuous administration represents a valid, safe, and economical therapeutic coverage that might be used in patients who have undergone conservative surgery for endometriosis [10, 11].”
BackgroundOral contraceptives and risk of endometriosis: a systematic review and meta-analysis
Vercellini, P., Eskenazi, B., Consonni, D., Somigliana, E., Parazzini, F., Abbiati, A., & Fedele, L. (2011) · Human Reproduction Update · doi:10.1093/humupd/dmq042 · Cited by 176
Anti-TNF- treatment for deep endometriosis-associated pain: a randomized placebo-controlled trial
Koninckx, P. R., Craessaerts, M., Timmerman, D., Cornillie, F., & Kennedy, S. (2008) · Human Reproduction · doi:10.1093/humrep/den177 · Cited by 165
Köhler, G., Faustmann, T. A., Gerlinger, C., Seitz, C., & Mueck, A. O. (2010) · International Journal of Gynecology & Obstetrics · doi:10.1016/j.ijgo.2009.08.020 · Cited by 159
Seracchioli, R., Mabrouk, M., Manuzzi, L., Vicenzi, C., Frasca, C., Elmakky, A., & Venturoli, S. (2009) · Human Reproduction · doi:10.1093/humrep/dep259 · Cited by 158 · cited 1×
“Furthermore, the continuous administration represents a valid, safe, and economical therapeutic coverage that might be used in patients who have undergone conservative surgery for endometriosis [10, 11].”
BackgroundCosson, M., Querleu, D., Donnez, J., Madelenat, P., Konincks, P., Audebert, A., & Manhes, H. (2002) · Fertility and Sterility · doi:10.1016/s0015-0282(01)03270-8 · Cited by 153
Progestogens for endometriosis: forward to the past
Vercellini, P. (2003) · Human Reproduction Update · doi:10.1093/humupd/dmg030 · Cited by 147 · cited 1×
“It allows good control of uterine bleeding; it has positive effect on calciummetabolism and no negative effects on the lipoprotein metabolism at low dosages [26].”
BackgroundAromatase inhibitors for the treatment of endometriosis
Pavone, M. E., & Bulun, S. E. (2012) · Fertility and Sterility · doi:10.1016/j.fertnstert.2012.08.053 · Cited by 138
Bayoglu Tekin, Y., Dilbaz, B., Altinbas, S. K., & Dilbaz, S. (2011) · Fertility and Sterility · doi:10.1016/j.fertnstert.2010.08.042 · Cited by 133
The role of the oxidative-stress in the endometriosis-related infertility
Augoulea, A., Mastorakos, G., Lambrinoudaki, I., Christodoulakos, G., & Creatsas, G. (2009) · Gynecological Endocrinology · doi:10.1080/09513590802485012 · Cited by 129
Walch, K., Unfried, G., Huber, J., Kurz, C., van Trotsenburg, M., Pernicka, E., & Wenzl, R. (2009) · Contraception · doi:10.1016/j.contraception.2008.07.017 · Cited by 128
Attardi, B. J., Burgenson, J., Hild, S. A., Reel, J. R., & Blye, R. P. (2002) · Molecular and Cellular Endocrinology · doi:10.1016/s0303-7207(01)00743-2 · Cited by 118 · cited 4×
“A 21-substituted-19-norprogestin, Telapristone acetate (CDB-4124) [127], has also been investigated in the treatment of endometriosis [128].”
BackgroundInfluentialAromatase expression in endometriotic tissues and cell cultures of patients with endometriosis
Velasco, I. (2006) · Molecular Human Reproduction · doi:10.1093/molehr/gal041 · Cited by 108 · cited 1×
“The estrogens produced in the endometrial tissue through aromatase promote the growth and invasion of endometrial lesion and favour the onset of pain and prostaglandin-mediated inflammation [59].”
BackgroundNorethisterone acetate in the treatment of colorectal endometriosis: a pilot study
Ferrero, S., Camerini, G., Ragni, N., Venturini, P. L., Biscaldi, E., & Remorgida, V. (2010) · Human Reproduction · doi:10.1093/humrep/dep361 · Cited by 107
WONG, A. Y. K., TANG, L. C. H., & CHIN, R. K. H. (2010) · Australian and New Zealand Journal of Obstetrics and Gynaecology · doi:10.1111/j.1479-828x.2010.01152.x · Cited by 82
Igarashi, M., Iizuka, M., Abe, Y., & Ibuki, Y. (1998) · Human Reproduction · doi:10.1093/humrep/13.7.1952 · Cited by 73
The inhibitory effect of celecoxib and rosiglitazone on experimental endometriosis
Olivares, C., Ricci, A., Bilotas, M., Barañao, R. I., & Meresman, G. (2011) · Fertility and Sterility · doi:10.1016/j.fertnstert.2011.05.063 · Cited by 65
Gonadotropin-releasing hormone agonist and add-back therapy: what do the data show?
Surrey, E. S. (2010) · Current Opinion in Obstetrics & Gynecology · doi:10.1097/gco.0b013e32833b35a7 · Cited by 64
ChwaliszC. Mattia-Goldberg, K., Lee, M., Elger, W., & Edmonds, A. (2004) · Fertility and Sterility · doi:10.1016/j.fertnstert.2004.07.212 · Cited by 43
Mei, L., Bao, J., Tang, L., Zhang, C., Wang, H., Sun, L., Ma, G., Huang, L., Yang, J., Zhang, L., et al. (2010) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2010.01.012 · Cited by 36
Cited by
Endometriosis: Epidemiology, Diagnosis and Clinical Management
Parasar, P., Ozcan, P., & Terry, K. L. (2017) · Current Obstetrics and Gynecology Reports · doi:10.1007/s13669-017-0187-1 · Cited by 753
GnRH and GnRH receptors in the pathophysiology of the human female reproductive system
Maggi, R., Cariboni, A. M., Marelli, M. M., Moretti, R. M., Andrè, V., Marzagalli, M., & Limonta, P. (2016) · Human Reproduction Update · doi:10.1093/humupd/dmv059 · Cited by 269
Oral contraceptives for pain associated with endometriosis
Brown, J., Crawford, T. J., Datta, S., & Prentice, A. (2018) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001019.pub3 · Cited by 199
Endometriosis: where are we and where are we going?
Greene, A. D., Lang, S. A., Kendziorski, J. A., Sroga-Rios, J. M., Herzog, T. J., & Burns, K. A. (2016) · Reproduction · doi:10.1530/rep-16-0052 · Cited by 187
Carvalho, N., Margatho, D., Cursino, K., Benetti-Pinto, C. L., & Bahamondes, L. (2018) · Fertility and Sterility · doi:10.1016/j.fertnstert.2018.07.003 · Cited by 96
Metadata
- Authors
- Zito, G., Luppi, S., Giolo, E., Martinelli, M., Venturin, I., Di Lorenzo, G., & Ricci, G.
- Venue
- BioMed Research International
- Publisher
- Wiley
- Published
- 2014
- Volume
- 2014
- Pages
- 1-12
- ISSN
- 1110-7243 (ISSN-L)
- 2314-6133
- 2314-6141
- OpenAlex
- W1976328610
- Cited by
- 93
- References
- 38
- FWCI
- 7.18
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.